
### [NCIT:C4024](http://purl.obolibrary.org/obo/NCIT_C4024)
**Label:** Esophageal Squamous Cell Carcinoma

**Subclasses:** [NCIT:C133442](http://purl.obolibrary.org/obo/NCIT_C133442) (Esophageal Squamous Cell Carcinoma by AJCC v7 Stage), [NCIT:C5019](http://purl.obolibrary.org/obo/NCIT_C5019) (Stage IV Esophageal Squamous Cell Carcinoma AJCC v7), [NCIT:C133443](http://purl.obolibrary.org/obo/NCIT_C133443) (Esophageal Squamous Cell Carcinoma by AJCC v8 Stage), [NCIT:C27422](http://purl.obolibrary.org/obo/NCIT_C27422) (Esophageal Undifferentiated Carcinoma), [NCIT:C5022](http://purl.obolibrary.org/obo/NCIT_C5022) (Stage I Esophageal Squamous Cell Carcinoma AJCC v7), [NCIT:C5023](http://purl.obolibrary.org/obo/NCIT_C5023) (Stage 0 Esophageal Squamous Cell Carcinoma AJCC v7), [NCIT:C8633](http://purl.obolibrary.org/obo/NCIT_C8633) (Recurrent Esophageal Squamous Cell Carcinoma), [NCIT:C5020](http://purl.obolibrary.org/obo/NCIT_C5020) (Stage III Esophageal Squamous Cell Carcinoma AJCC v7), [NCIT:C5021](http://purl.obolibrary.org/obo/NCIT_C5021) (Stage II Esophageal Squamous Cell Carcinoma AJCC v7), [NCIT:C95612](http://purl.obolibrary.org/obo/NCIT_C95612) (Esophageal Poorly Differentiated Squamous Cell Carcinoma), [NCIT:C95611](http://purl.obolibrary.org/obo/NCIT_C95611) (Esophageal Moderately Differentiated Squamous Cell Carcinoma), [NCIT:C27928](http://purl.obolibrary.org/obo/NCIT_C27928) (Alcohol-Related Esophageal Squamous Cell Carcinoma), [NCIT:C95610](http://purl.obolibrary.org/obo/NCIT_C95610) (Esophageal Well Differentiated Squamous Cell Carcinoma), [NCIT:C95608](http://purl.obolibrary.org/obo/NCIT_C95608) (Esophageal Spindle Cell Carcinoma), 

**Class expressions from DL-Learner:**

- [NCIT:C118376](http://purl.obolibrary.org/obo/NCIT_C118376) (FGF Gene Amplification) 57.69%
- [NCIT:C41380](http://purl.obolibrary.org/obo/NCIT_C41380) (FGF6 Gene Amplification) 53.85%
- [NCIT:C41379](http://purl.obolibrary.org/obo/NCIT_C41379) (FGF4 Gene Amplification) 53.85%
- [NCIT:C39629](http://purl.obolibrary.org/obo/NCIT_C39629) (CDKN2A Gene Inactivation) 53.85%
- [NCIT:C37189](http://purl.obolibrary.org/obo/NCIT_C37189) (del(17q25)) 53.85%
- [NCIT:C36704](http://purl.obolibrary.org/obo/NCIT_C36704) (FHIT Gene Inactivation) 53.85%
- [NCIT:C36652](http://purl.obolibrary.org/obo/NCIT_C36652) (CCND1 Gene Amplification) 53.85%
- [NCIT:C36649](http://purl.obolibrary.org/obo/NCIT_C36649) (EGFR Gene Amplification) 53.85%
- [NCIT:C36641](http://purl.obolibrary.org/obo/NCIT_C36641) (MYC Gene Amplification) 53.85%
- [NCIT:C36329](http://purl.obolibrary.org/obo/NCIT_C36329) (TP53 Gene Inactivation) 53.85%
- [NCIT:C32542](http://purl.obolibrary.org/obo/NCIT_C32542) (Esophageal Squamous Cell) 53.85%
- Thing 53.67%
- [NCIT:C3910](http://purl.obolibrary.org/obo/NCIT_C3910) (Molecular Abnormality) 45.46%
- [NCIT:C45581](http://purl.obolibrary.org/obo/NCIT_C45581) (Gene Amplification Abnormality) 44.88%
- [NCIT:C36344](http://purl.obolibrary.org/obo/NCIT_C36344) (Oncogene Deregulation) 44.88%


